載入中
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
前收盤價
US$2.19
+US$0.02 · +0.92%
盤中時間採用ET。市場資料可能有所延遲。
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
日內區間
目前US$2.19
52週區間
目前US$2.19
盤中時間採用ET。市場資料可能有所延遲。
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
日內區間
目前US$2.19
52週區間
目前US$2.19
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1611.9萬 USD | 1394.7萬 USD | 1518.2萬 USD | 1468.5萬 USD | 639.4萬 USD |
| 銷貨成本 | 811.3萬 USD | 711.5萬 USD | 1373.3萬 USD | 1430.1萬 USD | 676.8萬 USD |
| 毛利 | 800.6萬 USD | 683.2萬 USD | 144.9萬 USD | 38.4萬 USD | −37.4萬 USD |
| 研究與開發 | 4387.4萬 USD | 5058.5萬 USD | 4744.1萬 USD | 4579.7萬 USD | 2912.1萬 USD |
| 銷售、一般及管理費用 | 4258.3萬 USD | 5657.1萬 USD | 5895萬 USD | 5263萬 USD | 4220.1萬 USD |
| 營業費用 | 8599.8萬 USD | 1.07億 USD | 1.06億 USD | 9842.7萬 USD | 7132.2萬 USD |
| 利息收入 | 1152.2萬 USD | 1666.6萬 USD | 1776.4萬 USD | 460.2萬 USD | 32.6萬 USD |
| 利息支出 | — | — | — | — | 2.2萬 USD |
| 折舊和攤銷 | 610.4萬 USD | 617.6萬 USD | 557.8萬 USD | 394.2萬 USD | 255.8萬 USD |
| 營業利益 | −7799.2萬 USD | −1億 USD | −1.05億 USD | −9804.3萬 USD | −7169.6萬 USD |
| 淨利 | −7360萬 USD | −8659.9萬 USD | −8627.7萬 USD | −9296.6萬 USD | −7116.9萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$4.00
上漲空間 82.65%價格歷史記錄不可用
最高：US$4.00平均的：US$4.00最低：US$4.00評級樣本有限，僅4項
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI239.46萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF78萬0.00%954億 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC28.83萬0.02%13.17億 USD0.60%US$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM14萬0.12%1.17億 USD0.73%US$15.9402+0.25%
Avantis U.S. Small Cap Equity ETFAVSC13.35萬—30.82億 USD0.25%US$69.98+0.03%
U.S. Micro Cap Portfolio ETFDFMC8.21萬0.00%75.58億 USD0.43%US$57.813+0.20%
Invesco RAFI US 1500 Small-Mid ETFPRFZ5.06萬0.00%26.7億 USD0.36%US$53.16+0.64%
Dimensional - US Small Cap ETFDFAS3.38萬0.00%338.69億 USD0.31%US$78.35+0.32%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis U.S. Small Cap Equity ETFAVSCU.S. Micro Cap Portfolio ETFDFMCInvesco RAFI US 1500 Small-Mid ETFPRFZDimensional - US Small Cap ETFDFASAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
